PT  - JOURNAL ARTICLE
AU  - Sallard, Erwan
AU  - Lescure, François-Xavier
AU  - Burdet, Charles
AU  - Guedj, Jérémie
AU  - Yazdanpanah, Yazdan
AU  - Peiffer-Smadja, Nathan
TI  - Repurposed prophylaxis strategies for COVID-19: a review
AID  - 10.1101/2020.05.30.20117937
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.30.20117937
4099  - http://medrxiv.org/content/early/2020/06/03/2020.05.30.20117937.short
4100  - http://medrxiv.org/content/early/2020/06/03/2020.05.30.20117937.full
AB  - Introduction Efficient therapeutic strategies are needed to counter the COVID-19 pandemic, caused by the SARSCoV-2 virus. In a context where specific vaccines are not yet available, the containment of the pandemic would be facilitated with efficient prophylaxis.Methods We screened several clinical trials repositories and platforms in search of the prophylactic strategies that are investigated against COVID-19 in late April 2020.Results Up to April 27, 2020, we found 68 clinical trials targeting medical workers (n = 43, 63%), patients relatives (n = 16, 24%) or individuals at risk of severe COVID-19 (n = 5, 7%). (Hydroxy)chloroquine was the most frequently evaluated treatment (n = 46, 68%), before BCG vaccine (n = 5, 7%). Sixty-one (90%) clinical trials were randomized with a median of planned inclusions of 600 (IQR 255–1515).Conclusion The investigated prophylaxis strategies cover both pre- and post-exposure prophylaxis and study numerous immune enhancers and antivirals, although most research efforts are focused on (hydroxy)chloroquine.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No ethics approval is required for systematic reviews.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this article stems from registered clinical trials and is summarised in the supplementary table.